Company* | Product | Description | Indication | Status (Date) |
| | ||||
AUTOIMMUNE | ||||
Corixa Corp. | PVAC | Immunotherapeutic based | Psoriasis | Data from a Brazil trial showed clinical activity and safety but missed an endpoint of a 75% reduction in Psoriasis Area and Severity Index score at 12 weeks (11/7) |
CANCER | ||||
Access Pharmaceuticals Inc. (AMEX:AKC) | AP5280 | Novel platinum-polymer delivery system designed to deliver high concentrations of chemotherapeutic agents directly to solid tumors | Ovarian cancer | Company began enrolling patients in a Phase I/II ovarian cancer trial in Europe (11/26) |
Australian Cancer Technology Ltd.* (Australia) | Pentrix | Vaccine designed around | Cancer | Phase Ib/IIa trial results showed a strong immune response in all five patients who had completed the multidose trial to date; trial is in Australia (11/12) |
Guilford Pharmaceuticals | Gliadel Wafer | Biodegradable poly- | Malignant | Company elected to withdraw its regulatory application in Europe seeking an expanded indication for use during initial surgery for malignant glioma (11/20) |
Immuno-Designed Molecules SA* (France) | Eladem | Antitumor vaccine in which autologous dendritic cells loaded with recombinant PSA are injected into patients with recrudescent cancer after prostatectomy | Prostate | Phase I/II data showed that in six patients, the circulating prostate cancer cells that could be detected upon patient admission into the study had disappeared by six months; the trial was carried out in France (11/22) |
Munich Biotech | LipoPac | Compound based on the tendency of new blood vessels to bind and take up highly charged cationic liposomes | Gastrointestinal cancer | Company began a Phase Ib trial in Germany (11/8) |
Peregrine Pharmaceuticals Inc. (PPHM) | Cotara | A monoclonal antibody that carries the radioactive isotope iodine-131 to the necrotic core of solid tumor cancers | Glioma | European authorities granted orphan medicinal product designation to Cotara (11/25) |
YM BioSciences | Norelin | Vaccine targeting the gonadotropin-releasing hormone | Hormone- | Company enrolled the first patient in a 12-patient safety study being held in Canada (11/8) |
CARDIOVASCULAR | ||||
United Therapeutics | Remodulin | Treprostinil sodium | Pulmonary | The Israeli Ministry of Health approved Remodulin (11/4) |
CENTRAL NERVOUS SYSTEM | ||||
Amarin Corp. plc | -- | Once-daily morphine sulfate formulation | Moderate to | Companies submitted an NDA in Japan (11/12) |
INFECTION | ||||
Advanced Viral Research Corp. (OTC BB: ADVR) | Product | A "switch-type" immunomodulator; | AIDS-related wasting | Company initiated a Phase I trial in Israel (11/14) |
MISCELLANEOUS | ||||
Aphton Corp. | G17DT | Antigastrin immunogen | Gastroesophageal reflux disease | Company plans to initiate a clinical trial in Europe (11/6) |
ICOS Corp. (ICOS) and Eli Lilly and Co. | Cialis | Oral PDE5 inhibitor | Erectile | The European Commission granted marketing approval (11/14) |
Inhale Therapeutic Systems Inc. (INHL) | Somavert | Uses Inhale's | Acromegaly | Somavert was approved in Europe (11/21) |
Oxford | Zavesca | Oral capsule formulation of a glucosyltransferase inhibitor | Gaucher's | Zavesca received marketing authorization in Europe (11/26) |
| | ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||
NDA = New Drug Application | ||||
To read more on related topics, click on one of the words below.